IBEX 35
8.230,70-141,70(-1,69%)Euro Stoxx 50
3.599,55-41,82(-1,15%)Dólar/Euro
1,2085-0,0071(-0,58%)
Illumina, Inc. (ILMN)
Illumina, Inc.
5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
http://www.illumina.com
Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 7.700
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Francis A. deSouza | CEO, Pres & Director | N/A | N/A | 1971 |
| Mr. Sam A. Samad | CFO & Sr. VP | 626,7k | N/A | 1970 |
| Dr. Joydeep Goswami | Sr. VP of Corp. Devel. & Strategic Planning | 384,38k | N/A | 1971 |
| Ms. Aimee L. Hoyt | Chief People Officer & Sr. VP | 864,07k | N/A | 1971 |
| Mr. Robert P. Ragusa | Sr. VP of Global Quality & Operations | N/A | N/A | 1960 |
| Ms. Karen K. McGinnis | VP & Chief Accounting Officer | N/A | N/A | 1967 |
| Dr. Alexander Aravanis M.D., Ph.D. | Sr. VP & Chief Technology Officer | N/A | N/A | N/A |
| Mr. Steve Phillpott | Sr. VP & Chief Information Officer | N/A | N/A | N/A |
| Ms. Juliet Cunningham | VP of Investor Relations | N/A | N/A | N/A |
| Mr. Charles E. Dadswell | Sr. VP, Gen. Counsel & Sec. | N/A | N/A | 1959 |
Descripción
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. has a strategic collaboration with Myriad Genetics, Inc. to create a kit-based version of the myChoice companion diagnostic test for international markets. The company was founded in 1998 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de Illumina, Inc., a día 1 de diciembre de 2020, es 5. Las puntuaciones base son Auditoría: 1; Tablero: 4; Derechos de los accionistas: 6; Compensación: 7.
